Skip Navigation

JNCI Journal of the National Cancer Institute 2007 99(10):744-745; doi:10.1093/jnci/djk194
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Wilt, T. J.
Right arrow Articles by Ensrud, K. E.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wilt, T. J.
Right arrow Articles by Ensrud, K. E.
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2007. Published by Oxford University Press.

EDITORIALS

The If's, And's, or But's Regarding Bisphosphonates for Prostate Cancer

Timothy J. Wilt, Kristine E. Ensrud

Affiliations of authors: Department of Medicine, Minneapolis Veterans Affairs Center for Chronic Disease Outcomes Research, Minneapolis, MN; Department of Medicine, University of Minnesota School of Medicine, Minneapolis, MN

Correspondence to: Timothy J. Wilt, MD, MPH, Department of Medicine, Minneapolis VA Center for Chronic Disease Outcomes Research, 1 Veterans Dr (111-0), Minneapolis, MN 55417 (e-mail: tim.wilt@med.va.gov).

The first 150 words of the full text of this article appear below.

In 2007, an estimated 218890 men will be diagnosed with, and 27050 deaths will be attributed to, prostate cancer in the United States (1). Men with prostate cancer are at increased risk for skeletal related complications. Bony metastases can result in pain, disability, and pathologic fractures. Use of androgen deprivation therapy (ADT) for primary or palliative treatment is associated with an increased rate of bone loss and higher risk of nonpathologic fractures (2). ADT use has increased two- to fourfold in the past 10 years, and up to 45% of white men receiving conservative management for early-stage prostate cancer receive ADT (3). An estimated 3000 excess fractures per year have been attributed to the use of ADT in older men (2).

Bisphosphonates, which are primarily used to treat postmenopausal osteoporosis, are increasingly prescribed for men with prostate cancer because randomized trials suggest . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

Oral Sodium Clodronate for Nonmetastatic Prostate Cancer—Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873)
Malcolm D. Mason, Matthew R. Sydes, John Glaholm, Ruth E. Langley, Robert A. Huddart, Michael Sokal, Mark Stott, Anne C. Robinson, Nicholas D. James, Mahesh K. B. Parmar, and David P. Dearnaley
J Natl Cancer Inst 2007 99: 765-776. [Abstract] [Full Text] [PDF]

IN THIS ISSUE
J Natl Cancer Inst 2007 99: 741. [Extract] [Full Text] [PDF]